Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patientsVisa övriga samt affilieringar
2020 (Engelska)Ingår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 189, nr 4, s. 661-671Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0 center dot 6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0 center dot 4 (95% CI: -0 center dot 7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.
Ort, förlag, år, upplaga, sidor
WILEY , 2020. Vol. 189, nr 4, s. 661-671
Nyckelord [en]
Burkitt lymphoma; immunochemotherapy; survival; prognosis; real-world patients
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:liu:diva-163706DOI: 10.1111/bjh.16425ISI: 000510759700001PubMedID: 32017050OAI: oai:DiVA.org:liu-163706DiVA, id: diva2:1394315
Anmärkning
Funding Agencies|US National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Danish Cancer SocietyDanish Cancer Society; Danish North Jutland Region
2020-02-182020-02-182021-05-04